Neovascular Age-related Macular Degeneration
4 competing products in clinical development for Neovascular Age-related Macular Degeneration.
Pipeline by Phase
Phase 11
Phase 1/21
Phase 22
All Products (4)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | Completed | 44 |
| UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | Completed | 44 |
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | Completed | 33 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | Completed | 33 |